Intensive blood pressure control in type 2 diabetes: a meta-analysis of randomized controlled trials - Takeaways - MDSpire

Intensive blood pressure control in type 2 diabetes: a meta-analysis of randomized controlled trials

  • By

  • Zeguang Liu

  • Junfeng Wang

  • Chenguang Niu

  • June 15, 2026

  • 0 min

Share

  • 1

    This meta-analysis included nine randomized controlled trials with 34,260 participants comparing intensive and conventional blood pressure control in T2D.

  • 2

    Intensive blood pressure control significantly reduced the risk of major adverse cardiovascular events (MACE) compared to conventional control.

  • 3

    Among MACE components, intensive treatment significantly lowered the risk of stroke but showed no significant differences for heart failure or myocardial infarction.

  • 4

    Subgroup analyses indicated potential benefits of targeting systolic blood pressure below 130 mm Hg with explicit diastolic blood pressure targets.

  • 5

    Intensive treatment was associated with a borderline increased risk of hypotension but not with other adverse events.

Original Source(s)

Intensive blood pressure control in type 2 diabetes: a meta-analysis of randomized controlled trials

  • by Zeguang Liu, Junfeng Wang, Chenguang Niu

  • June 15, 2026

Related Content

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.